Kannel WBLipids, diabetes and coronary heart disease: insights from the Framingham Study. Am Heart J1985;110: 1100-07.
2.
Stamler J., Vaccaro O., Neaton JD, Wentworth D.Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care1993;16:434-44.
3.
Gu K., Cowie CC, Harris MIMortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care1998;21:1138-45.
4.
Sprafka JM, Burke GL, Folsom AR et al. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival. The Minnesota Heart Survey . Diabetes Care1991;14:537-43.
5.
Gu K., Cowie CC, Harris MIDiabetes and decline in heart disease mortality in US adults. JAMA1999;281:1291-7.
6.
Diabetes atlas. Available from www.eatlas.idf.org/prevalence
7.
Haffner SM, Lehto S., Rönnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction . N Engl J Med1998;339:229-34.
8.
Juutilainen A., Pyorala K., Lehto S. et al. Type 2 diabetes as a 'coronary heart disease equivalent'. An 18-year prospective population-based study in Finnish subjects. Diabetes Care2005;28:2901-07.
9.
Hu FB, Stampfer MJ, Haffner SM et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care2002; 25:1129-34.
10.
The IDF consensus worldwide definition of the metabolic syndrome . Available from http://www.idf.org
11.
Lamarche B. , Tchernof A., Moorjani S. et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation1997;95:69-75.
12.
The FIELD study investigators.Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial . Lancet2005; 366:1849-61.
13.
Chapman MJFibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis2003;171:1-13.
14.
Staels B., Dallongeville J., Auwerx J. et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism . Circulation1998;98:2088-93.
15.
Forcheron F. , Cachefo A., Thevenon S. et al. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes2002;51:3486-91.
16.
Feher MD, Caslake M., Foxton J. et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev1999;15:395-9.
17.
Vakkilainen J., Steiner G., Ansquer JC et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Study (DAIS). Circulation2003;107: 1733-7.
18.
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes; the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet2001; 357:905-10.
19.
Staels B., Koenig W., Habib A. et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature1998;393:790-3.
20.
Koh KK, Han SW, Quon MJ et al. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia . Diabetes Care2005; 28:1419-24.
21.
Rubins HB, Robins SJ, Collins D. et al. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med2002; 162:2597-604.
22.
Pyörälä K., Pedersen TR, Kjekshus J. et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care1997;20:614-20.
23.
Haffner SM, Alexander CM, Cook TJ et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch Intern Med1999; 159:2661-7.
24.
Goldberg RB, Mellies MJ, Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation1998;98:2513-19.
25.
Heart Protection StudyCollaborative Group.MRC/ BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361:2005-16.
26.
Sever PS, Dahlöf B., Poulter N. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet2003;361:1149-58.
27.
Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004; 364:685-96.
28.
Wanner C., Krane V., Marz W. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med2005;353: 238-48.
29.
Kendall DM, Bergenstal RMComprehensive management of patients with type 2 diabetes: establishing priorities of care. Am J Manag Care2001;7:S327-43.
30.
Baigent C., Keech A., Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005;366: 1267-78.
31.
Ansquer JC, Foucher C., Rattier S. et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis2005;45:485-93.
32.
Meade T., Zuhrie R., Cook C. et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ2002;325:1139.
33.
Cusick M., Meleth AD, Agran E. et al. Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. Diabetes Care2005;28:617-25.
34.
Stratton IM , Kohner EM, Aldington SJ et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis . Diabetologia2001;44:156-63.
35.
Chew EY, Klein ML, Ferris FL et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol1996;114:1079-84.
36.
Mogensen CE , Poulsen PLMicroalbuminuria, glycemic control, and blood pressure predicting outcome in diabetes type 1 and type 2. Kidney Int Suppl2004;66: S40-41.
37.
Stratton IM , Adler AI, Neil AW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ2000;321:405-12.
38.
Gaede P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med2003;348:383-93.
39.
Burke GLArterial wall thickness is associated with prevalent cardiovascular disease in middle aged adults: the Atherosclerosis Risk in Communities (ARIC) study . Stroke1995;26:386-91.
40.
Feher MD, Hepburn AL, Hogarth MB et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford)2003; 42:321-5.
